IL2 and glioblastoma: Patients with glioblastoma (GBM) are locally and systemically immunosuppressed [1,2] as lymphocyte counts, mainly CD4+, are reduced and T-cell proliferation, in response to interleukin-2 (IL-2), is impaired [3].